Figure 5.

Hazards Ratios and 95% Confidence Interval for longitudinal studies using Echocardiography to estimate LVH as predictor of clinical outcomes.

Composite 1 - fatal or nonfatal myocardial infarction, sudden death, fatal or nonfatal stroke, other cardiovascular deaths, severe heart failure requiring hospitalization, severe renal failure requiring dialysis, documented angina, transient ischemic attack, and peripheral occlusive arterial disease verified by angiography; HF – heart failure; MI-indep – myocardial infarct independent; CAD – coronary artery disease; CHD - coronary heart disease; Composite 2: Fatal/nonfatal coronary heart disease, stroke, congestive heart failure, other cardiovascular disease. Composite 3 - myocardial infarction (MI), coronary revascularization, atrial fibrillation (AF), congestive heart failure (CHF), transient ischemic attack (TIA), stroke, or cardiovascular death; TIA - Transient ischemic attack; Composite 4 - sudden death, which is unexpected death that occurs within 24 h without external causes; cerebrovascular events including stroke or transient ischemic attack; cardiac events including heart failure, angina pectoris, or acute myocardial infarction; renal events including sCr more than or equal to 4.0 mg/dl, doubling of the sCr (however, sCr 2.0 mg/dl is not regarded as an event), or end-stage renal disease; and vascular events including dissecting aortic aneurysm or arteriosclerotic occlusion of a peripheral artery.

LVH^a – hypertrophy defined by non indexed LVM; LVH^b– hypertrophy defined by LVM indexed by BSA; LVH^c– hypertrophy defined by LVM indexed by BSA^1.5; LVH^d – hypertrophy defined by LVM indexed by height; LVH^e– hypertrophy defined by LVM indexed by height^2.7; LVH^f– hypertrophy defined by LVM indexed by height^2.13. LVH^a to LVH^f refer to the whole population included in the study.